Elanco Animal Health (NYSE:ELAN) Price Target Raised to $26.00

Elanco Animal Health (NYSE:ELAN) had its target price increased by Morgan Stanley from $23.00 to $26.00 in a research report report published on Wednesday morning,Benzinga reports. The firm currently has an equal weight rating on the stock.

Several other equities analysts have also recently issued reports on ELAN. Wall Street Zen cut shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. Citigroup increased their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. TD Cowen raised their price target on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Weiss Ratings cut shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Elanco Animal Health presently has an average rating of “Moderate Buy” and an average price target of $28.73.

Elanco Animal Health Stock Up 0.5%

Elanco Animal Health stock opened at $24.90 on Wednesday. The business’s 50-day moving average price is $24.01 and its 200 day moving average price is $23.97. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. The firm has a market cap of $12.44 billion, a price-to-earnings ratio of -49.80, a price-to-earnings-growth ratio of 1.62 and a beta of 1.68. Elanco Animal Health has a 52 week low of $13.39 and a 52 week high of $27.72.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.28 billion. During the same period in the previous year, the company posted $0.37 earnings per share. Elanco Animal Health’s revenue for the quarter was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, sell-side analysts anticipate that Elanco Animal Health will post 1.11 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Rajeev A. Modi purchased 4,911 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were purchased at an average price of $20.35 per share, with a total value of $99,938.85. Following the purchase, the insider owned 160,812 shares of the company’s stock, valued at $3,272,524.20. The trade was a 3.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jeffrey N. Simmons purchased 4,971 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The stock was bought at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the purchase, the chief executive officer directly owned 171,971 shares in the company, valued at $3,454,897.39. This trade represents a 2.98% increase in their position. The disclosure for this purchase is available in the SEC filing. 1.14% of the stock is owned by insiders.

Hedge Funds Weigh In On Elanco Animal Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. NewEdge Advisors LLC increased its stake in shares of Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after purchasing an additional 627 shares in the last quarter. Root Financial Partners LLC lifted its stake in Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after buying an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. acquired a new stake in Elanco Animal Health in the 4th quarter worth about $41,000. Torren Management LLC acquired a new stake in Elanco Animal Health in the 4th quarter worth about $46,000. Finally, Bessemer Group Inc. increased its stake in Elanco Animal Health by 33.2% during the 1st quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after buying an additional 525 shares in the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.